PRESBIA PLC (NASDAQ:LENS) Files An 8-K Regulation FD Disclosure

Item7.01 Regulation FD Disclosure.

As an Irish public limited company, Presbia PLC (the Company) is
required, in connection with its annual general shareholders
meeting, to send or make available to its shareholders the
Companys Irish statutory accounts for the year ended December31,
2016 and related reports (the Irish Statutory Accounts). A copy
of the Irish Statutory Accounts is attached hereto as Exhibit
99.1. Although the Irish Statutory Accounts are based on the
financial statements the Company prepared in accordance with U.S.
generally accepted accounting principles and filed as a part of
its Annual Report on Form 10-K, the Irish Statutory Accounts
include disclosures and presentation formats required by the
Republic of Irelands Irish Companies Act 2014.

The Irish Statutory Accounts will be sent or made available to
shareholders in advance of the Companys 2017Annual General
Meeting, as required by Irish law.

In accordance with General Instruction B.2 of Form 8-K, the
information in this Item7.01 of this Current Report on Form 8-K,
including Exhibit 99.1, shall not be deemed filed for the
purposes of Section18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Exchange Act or the
Securities Act of 1933, as amended, except as shall be expressly
set forth by reference in such a filing.

Item9.01. Financial Statements and Exhibits.

Presbia PLC Exhibit
EX-99.1 2 d415919dex991.htm EX-99.1 EX-99.1 EXHIBIT 99.1 Presbia PLC Report and Consolidated Financial Statements for the year ended 31 December 2016 PRESBIA PLC REPORT AND CONSOLIDATED FINANCIAL STATEMENTS     CONTENTS    PAGE   COMPANY INFORMATION      2   DIRECTOR’S REPORT      3 – 6   STATEMENT OF DIRECTORS’ RESPONSIBILITIES      7   INDEPENDENT AUDITOR’S REPORT      8 – 9   CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS      10   CONSOLIDATED BALANCE SHEET      11   COMPANY BALANCE SHEET      12   CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS’ EQUITY      13   COMPANY STATEMENT OF CHANGES IN SHAREHOLDERS’ EQUITY      14   CONSOLIDATED STATEMENT OF CASH FLOWS      15   COMPANY STATEMENT OF CASH FLOWS      16   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS      17 – 34     1 PRESBIA PLC COMPANY INFORMATION     DIRECTORS    Todd Cooper    Randy Thurman    Richard Ressler    Vladimir Feingold    Zohar Loshitzer    Gerd Auffarth    Gerald Farrell    Robert Cresci SECRETARY    Jarett Fenton REGISTERED OFFICE    120/121 Baggot Street Lower    Dublin 2    Ireland REGISTERED NUMBER OF INCORPORATION    539137 SOLICITORS    Arthur Cox    10 Earlsfort Terrace    Dublin 2    Ireland AUDITOR    Moore Stephens LLP    150 Aldersgate Street    London    EC1A 4AB BANKERS    Allied Irish Bank    Bank Centre Ballsbridge Dublin 4   2 PRESBIA PLC DIRECTORS’ REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2016     The directors present their report and audited consolidated financial statements for the year ended 31 December 2016. The directors have elected to prepare the consolidated financial statements of Presbia PLC in accordance with Section 279 of the Companies Act 2014,…
To view the full exhibit click here
About PRESBIA PLC (NASDAQ:LENS)

Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States. The Company’s lens, referred to as the microlens, is a miniature lens designed to be surgically implanted in a patient’s eye to improve that patient’s ability to see objects at close distances. The microlens is a disc shaped lens that has a refractive zone in the periphery designed to improve near vision problems associated with presbyopia and a central zone that is designed to improve distance vision. The Company’s solution is a standalone solution for plano presbyopes, or those individuals suffering from presbyopia but do not have any other visual disorders.